The role of tumor necrosis factor-α in the pathogenesis of anorexia and bulimia nervosa, cancer cachexia and obesity

Medical Hypotheses

Volumn 47, Issue 6, 1996, Pages 423-438

  Holden, R J ^a   Pakula, I S ^b  

^a UNIVERSITY OF WOLLONGONG   (Australia)

^b South Eastern Sydney and Illawarra Area Health Service   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

BETA ENDORPHIN; CHOLECYSTOKININ; CORTICOTROPIN RELEASING FACTOR; CYTOKINE; INTERLEUKIN 2; INTERLEUKIN 4; NEUROPEPTIDE; NORADRENALIN; PEPTIDE YY; SEROTONIN; TUMOR NECROSIS FACTOR ALPHA; VASOACTIVE INTESTINAL POLYPEPTIDE;

ANOREXIA NERVOSA; BODY WEIGHT; BULIMIA; CACHEXIA; HUMAN; NEUROTRANSMISSION; NONHUMAN; OBESITY; PATHOGENESIS; PRIORITY JOURNAL; REVIEW;

EID: 0029800509     PISSN: 03069877     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0306-9877(96)90153-X     Document Type: Article

References (148)

1. Parry-Jones WL, Parry-Jones B. Implications of historical evidence for the classification of eating disorders. A dimension overlooked in DSM-III-R and ICD-10. Br J Psychiatry 1994; 165: 287-292.
2. Parry-Jones B. Merycism or rumination disorder. A historical investigation and current assessment. Br J Psychiatry 1994; 165: 303-314.
3. Parry-Jones B, Parry-Jones-W L. Self-mutilation in four historical cases of bulimia. Br J Psychiatry 1993; 163: 394-402.
4. Sharp C W. Anorexia nervosa and depression in a woman blind since the age of nine months. Can J Psychiatry 1993; 38: 469-471.
5. Waller G. Borderline personality disorder and perceived family dysfunction in the eating disorders. J Nerv Ment Dis 1994; 182: 541-546.
6. Waller G. Sexual abuse and eating disorders. Borderline personality disorder as a mediating factor? Br J Psychiatry 1993; 162: 771-775.
7. Vanderlinden J, Vandereycken W, van Dyck R, Vertommen H. Dissociative experiences and trauma in eating disorders. Int J Eat Disord 1993; 13: 187-193.
8. Skodol A E, Oldham J M, Hyler S E, Kellman H D, Doidge N, Davies M. Comorbidity of DSM-III-R eating disorders and personality disorders. Int J Eat Disord 1993; 14: 403-416.
9. Schmidt U, Jiwany A, Treasure J. A controlled study of alexithymia in eating disorders. Compr Psychiatry 1993; 34: 54-58.
10. Jimerson D C, Wolfe B E, Franko D L, Covino N A, Sifneos P E. Alexithymia ratings in bulimia nervosa: clinical correlates. Psychosom Med 1994; 56: 90-93.
11. Dulit R A, Fyer M R, Leon A C, Brodsky B S, Frances A J. Clinical correlates of self-mutilation in borderline personality disorder. Am J Psychiatry 1994; 151: 1305-1311.
12. Fahy T, Eisler I. Impulsivity and eating disorders. Br J Psychiatry 1993; 162: 193-197.
13. Holderness C C, Brooks-Gunn J, Warren M P. Co-morbidity of eating disorders and substance abuse review of the literature. Int J Eat Disord 1994; 16: 1-34.
14. Fahy T A, Osacar A, Marks I. History of eating disorders in female patients with obsessive-compulsive disorder. Int J Eat Disord 1993; 14: 439-443.
15. Kasvikis Y G, Tsakiris F, Marks I M, Basoglu M, Noshirvani H F. Past history of anorexia nervosa in women with obsessive-compulsive disorder. Int J Eat Disord 1986; 5: 1069-1075.
16. Thiel A, Broocks A, Ohlmeier M, Jacoby G E, Schussler G. Obsessive-compulsive disorder among patients with anorexia nervosa and bulimia nervosa. Am J Psychiatry 1995; 152:72-75.
17. Newton J R, Freeman C P, Munro J. Impulsivity and dys-control in bulimia nervosa: is impulsivity an independent phenomenon or a marker of severity? Acta Psychiatr Scand 1993; 87: 389-394.
18. O'Rourke D A, Wurtman J J, Wurtman R J et al. Aberrant snacking patterns and eating disorders in patients with obsessive compulsive disorder. J Clin Psychiatry 1994; 55: 445-447.
19. Johnson W G, Jarrell M P, Chupurdia K M, Williamson D A. Repeated binge/purge cycles in bulimia nervosa: role of glucose and insulin. Int J Eat Disord 1994; 15: 331-341.
20. Christensen L, Redig C. Effect of meal composition on mood. Behav Neurosci 1993; 107: 346-353.
21. Ballenger J C, Goodwin F K, Major L F, Brown G L. Alcohol and central serotonin metabolism in man. Arch Gen Psychiatry 1979; 36: 224-227.
22. Roth B L. Multiple serotonin receptors: clinical and experimental aspects. Ann Clin Psychiatry 1994; 6: 67-78.
23. Wallin M S, Rissanen A M. Food and mood: relationship between food, serotonin and affective disorders. Acta Psychiatr Scand 1994; 377 (suppl): 36-40.
24. Crow S J, Mitchell J E. Rational therapy of eating disorders. Drugs 1994; 48: 372-379.
25. Golden N H, Shenker I R. Amenorrhea in anorexia nervosa. Neuroendocrine control of hypothalamic dysfunction. Int J Eat Disord 1994; 16: 53-60.
26. McClain C J, Humphries L L, Hill K K, Nicki N J. Gastro-intestinal and nutritional aspects of eating disorders. J Am Coll Nutr 1993; 12: 466-474.
27. Newton J R, Freeman C P, Hannan W J, Cowen S. Osteoporosis and normal weight bulimia nervosa-which patients are at risk? J Psychosom Res 1993; 37: 239-247.
28. Holman R T, Adams C E, Nelson R A et al. Patients with anorexia nervosa demonstrate deficiencies of selected essential fatty acids, compensatory changes in nonessential fatty acids and decreased fluidity of plasma lipids. J Nutr 1995; 125: 901-907.
29. Horrobin D F, Kruger M. Essential fatty acids and osteoporosis: a review.
30. Holden R J. The estrogen connection: the etiological relationship between diabetes, cancer, rheumatoid arthritis and psychiatric disorders. Med Hypotheses 1995; 45: 169-189.
31. Kaye W H, Weltzin T F. Neurochemistry of bulimia nervosa. J Clin Psychiatry 1991; 52: 21-28.
32. Lydiard R B. Neuropeptides and anxiety: focus on chole-cystokinin. Clin Chem 1994; 40: 315-318.
33. Ferin M, Van Vugt D, Wardlaw S. The hypothalamic control of the menstrual cycle and the role of the endogenous opiod peptides. Recent Prog Horm Res 1984; 40: 441-485.
34. Knuth U A, Friesen H G. Changes of beta-endorphin and somatostatin concentrations in different hypothalamic areas of female rats after chronic starvation. Life Sci 1983; 827-833.
35. Gambert S R, Garthwaite T L, Pontzer C H, Hagen T C. Fasting associated with decrease in hypothalamic β-endorphin. Science 1980; 210: 1271-1272.
36. Atkinson R L. Naloxone decreases food intake in obese humans. J Clin Endocrinol Metab 1982; 55: 196-198.
37. Van den Bergh P, Dobber R, Ramlal S, Rozing J, Nagelkerken L. Role of opioid peptides in the regulation of cytokine production by murine CD4+ T cells. Cell Immunol 1994; 154: 109-122.
38. Tamai H, Takemura J, Kobayashi N, Matsubayashi S, Matsukura S, Nakagawa T. Changes in plasma cholecystokinin concentrations after oral glucose tolerance test in anorexia nervosa before and after therapy. Metabolism 1993; 42: 581-584.
39. Wlodarczyk-Bisaga K, Bisaga A. [Selected issues of biological aspects of eating disorders]. Psychiatr Pol 1994; 28: 579-591.
40. Bessler H, Karp L, Notti I et al. Cytokine production in anorexia nervosa. Clin Neuropharmacol 1993; 16: 237-243.
41. Schattner A, Tepper R, Steinbock M, Schoenfeld A, Vaisman N, Hahn T. [Cytokines in anorexia nervosa - nutritional or neuroimmunal changes?] Harefuah 1992; 123: 245-247, 308.
42. Moore R, Mills I H, Forster A. Naloxone in the treatment of anorexia nervosa: effect on weight gain and lipolysis. J R Soc Med 1981; 74: 129-131.
43. Marrazzi M A, Luby E D. An auto-addiction opioid model of chronic anorexia nervosa. Int J Eat Dis 1986; 5: 191-208.
44. Czlonkowski A, Stein C, Herz A. Peripheral mechanisms of opioid antinociception in inflammation: involvement of cytokines. Eur J Pharmacol 1993; 242: 229-235.
45. Hotamisligil G S, Spiegelman B M. Tumor necrosis factor alpha: a key component of the obesity-diabetes link. Diabetes 1994; 43: 1271-1278.
46. Hotamisligil G S, Budavari A, Murray D L, Spiegelman B M. Reduced tyrosine kinase activity of the insulin receptor in obesity-diabetes. Central role of tumor necrosis factor-alpha. J Clin Invest 1994; 94: 1543-1549.
47. Hotamisligil G S, Murray D L, Choy L N, Spiegelman B M. Tumor necrosis factor α inhibits signaling from the insulin receptor. Proc Natl Acad Sci USA 1994; 91: 4854-4858.
48. Mehta V K, Hao W, Brooks-Worrell B M, Palmer J P. Low-dose interleukin 1 and tumor necrosis factor individually stimulate insulin release but in combination cause suppression. Eur J Endocrinol 1994; 130: 208-214.
49. Jhala U, Baly D L. Effect of chronic IL-1 beta infusion on glucose homeostasis and pancreatic insulin secretion. Life Sci 1994; 54: 413-422.
50. Berg M, Fraker D L, Alexander H R. Characterization of differentiation factor/leukaemia inhibitory factor effect on lipoprotein lipase activity and mRNA in 3T3-L1 adipocytes. Cytokine 1994; 6: 425-432.
51. Tracey K J, Cerami A. Tumor necrosis factor and regulation of metabolism in infection: role of systemic versus tissue levels. PSEBM 1992; 200: 233-239.
52. Petruschke T, Hauner H. Tumor necrosis factor-alpha prevents the differentiation of human adipocyte precursor cells and causes delipidation of newly developed fat cells. J Clin Endocrinol Metab 1993; 76: 742-747.
53. Fantino M, Wieteska L. Evidence for a direct central anorectic effect of tumor-necrosis-factor-alpha in the rat. Physiol Behav 1993; 53: 477-483.
54. Borkman M, Storlein L H, Pan D A, Jenkins A B, Chisholm D J, Campbell L V. The relation between insulin sensitivity and the fatty-acid composition of skeletal-muscle phospholipids. N Engl J Med 1993; 328: 238-244.
55. Brekke O L, Espevik T, Bardal T, Bjerve K S. Effects of n-3 and n-6 fatty acids on tumor necrosis factor cytotoxicity in WEHI fibrosarcoma cells. Lipids 1992; 27: 161-168.
56. Hotamisligil G S, Arner P, Caro J F, Atkinson R L, Spiegelman B M. Increased adipose tissue expression of tumor necrosis factor-alpha in human obesity and insulin resistance. J Clin Invest 1995; 95: 2409-2415.
57. Best C L, Pudney J, Anderson D J, Hill J A. Modulation of human granulosa cell steroid production in vitro by tumor necrosis factor alpha: implications of white blood cells in culture. Obstet Gynecol 1994; 84: 121-127.
58. Wuttke W, Jarry H, Pitzel L, Knoke I, Spiess S. Luteotrophic and luteolytic actions of ovarian peptides. Hum Reprod 1993; 8: 141-146.
59. Baranowska B, Rozbicka G, Jeske W, Abdel-Fattah M H. The role of endogenous opiates in the mechanism of inhibited luteinizing hormone (LH) secretion in women with anorexia nervosa: the effect of naloxone on LH folliclestimulating-hormone, prolactin and β-endorphin secretion. J Clin Endocrinol Metab 1984; 59: 412-416.
60. Suzuki H, Sugiyama E, Tunru I S et al. Suppressive effect of interleukin-4 (IL-4) on IL-6 production by adherent rheumatoid synovial cells. Clin Immunol Immunopathol 1993; 66: 67-72.
61. Chao C C, Molitor T W, Hu S. Neuroprotective role of IL-4 against activated microglia. J Immunol 1993; 151: 1473-1481.
62. Giugliano D, Ceriello A, Di Pinto P, Saccomanno F, Gentile S, Cappiapuoti F. Impaired insulin secretion in human diabetes mellitus. The effect of naloxone-induced opiate receptor blockade. Diabetes 1982; 31: 367-370.
63. Tessitore L, Costelli P, Baccino F M. Humoral mediation for cachexia in tumor-bearing rats. Br J Cancer 1993; 67: 15-23.
64. Sakurai Y, Zhang X U, Wolfe R R. Short-term effects of tumor necrosis factor on energy and substrate metabolism in dogs. J Clin Invest 1993; 91: 2437-2445.
65. Yang Z J, Koseki M, Meguid M M, Gleason J R, Debonis D. Synergistic effect of rhTNF-alpha and rhIL-1 alpha in inducing anorexia in rats. Am J Physiol 1994; 267: R1056-R1064.
66. Yamada K, Takane N, Otabe S, Inada C, Inoue M, Nonaka K. Pancreatic beta-cell-selective production of tumor necrosis factor-alpha induced by interleukin-1. Diabetes 1993; 42: 1026-1031.
67. Zalcman S, Green-Johnson J M, Murray L et al. Cytokine-specific central monoamine alterations induced by interleukin-1, -2 and -6. Brain Res 1994; 643: 40-49.
68. Mohnakumar P S, Thyagarajan S, Quadri S K. Interleukin-1β increases 5-hydroxyindoleacetic acid release in the hypothalamus in vivo. Brain Res Bull 1993; 31: 745-748.
69. Smith B K, Kluger M J. Anti-TNF-alpha antibodies normalized body temperature and enhanced food intake in tumorbearing rats. Am J Physiol 1993; 265: R615-R619.
70. Smith B K, Conn C A, Kluger M J. Experimental cachexia: effects of MCA sarcoma in the Fischer rat. Am J Physiol 1993; 265: R376-R384.
71. Pomeroy C, Eckert E, Hu S et al. Role of interleukin-6 and transforming growth factor-beta in anorexia nervosa. Biol Psychiatry 1994; 36: 836-839.
72. Ganguli R, Yang Z, Shurin G et al. Serum interleukin-6 concentration in schizophrenia: elevation associated with duration of illness. Psychiatry Res 1994; 51: 1-10.
73. Maes M, Meltzer H Y, Bosnians E. Immune-inflammatory markers in schizophrenia: comparison to normal controls and effects of clozapine. Acta Psychiatr Scand 1994; 89: 346-351.
74. Maes M, Scharpé S, Meltzer H Y et al. Relationships between interleukin-6 activity, acute phase proteins, and function of the hypothalamic-pituitary-adrenal axis in severe depression. Psychiatr Res 1993; 49 11-27.
75. Huang W, Wang D S, Li X Y, Wu W Z, Ni G C. Expression levels of IL-6 mRNA in PBMNCs from patients with IDDM, NIDDM and normals by RT-PCR procedure. Chin Med J Engl 1993; 106: 893-897.
76. Tanabe M, Ochi T, Tomita T et al. Remarkable elevation of interleukin 6 and interleukin 8 levels in the bone marrow serum of patients with rheumatoid arthritis. J Rheumatol 1994; 21: 830-835.
77. Lepore L, Pennesi M, Saletta S, Perticarari S, Presani G, Prodan M. Study of IL-2, IL-6, TNF alpha, IFN gamma and beta in the serum and synovial fluid of patients with juvenile chronic arthritis. Clin Exp Rheumatol 1994; 12: 561-565.
78. Sacerdote P, Bianchi M, Manfredi B, Panerai A E. Intracerebroventricular interleukin-1 alpha increases immunocyte beta-endorphin concentrations in the rat: involvement of corticotropin-releasing hormone, catecholamines, and serotonin. Endocrinology 1994; 135: 1346-1352.
79. Pearce B D, Hobbs M V, McGraw TS, Buchmeier M J. Cytokine induction during T-cell-mediated clearance of mouse hepatitis virus from neurons in vivo. J Virol 1994; 68: 5483-5495.
80. Cavallo M G, Baroni M G, Toto A et al. Viral infection induces cytokine release by beta islet cells. Immunology 1992; 75: 664-668.
81. Byerley L O, Alcock N W, Starnes HF Jr. Sepsis-induced cascade of cytokine mRNA expression: correlation with metabolic changes. Am J Physiol 1992; 262: E728-E735.
82. Roubenoff R, Roubenoff R A, Ward L M, Holland S M, Hellmann D B. Rheumatoid cachexia: depletion of lean body mass in rheumatoid arthritis. Possible association with tumor necrosis factor. J Rheumatol 1992; 19: 1505-1510.
83. Maury C P J, Teppo A-M. Tumor necrosis factor in the serum of patients with systemic lupus erythematosus. Arthritis Rheum 1989; 32: 146-150.
84. Minamishima I, Ohga S, Ishii E et al. Serum interleukin-6 and fever at diagnosis in children with acute leukemia. Am J Pediatr Hematol Oncol 1993; 15: 239-244.
85. Nolten WE, Goldstein D, Lindstrom M et al. Effects of cytokines on the pituitary-adrenal axis in cancer patients. J Interferon Res 1993; 13: 349-357.
86. Gross M J, Kahn J P, Laxenaire M, Nicolas J P, Burlet C. Corticotropin-releasing factor and anorexia nervosa: reactions of the hypothalamus-pituitary-adrenal axis to neurotropic stress. Ann Endocrinol Paris 1994; 55: 221-228.
87. Lissoni P, Barni S, Rovelli F et al. Neuroendocrine effects of subcutaneous interleukin-2 injection in cancer patients. Tumori 1991; 77: 212-215.
88. Davis L S, Kavanaugh A F, Nichols L A, Lipsky P E. Induction of persistent T cell hyporesponsiveness in vivo by monoclonal antibody to ICAM-1 in patients with rheumatoid arthritis. J Immunol 1995; 154: 3525-3537.
89. Fort J G, Smith J B, Abruzzo J L. Abnormal T-cell function in patients with psoriatic arthritis: evidence for decreased interleukin 2 production. Rheumatol Int 1993; 13: 151-154.
90. Anderson PM, Sorenson MA. Effects of route and formulation on clinical pharmacokinetics of interleukin-2. Clin Pharmacokinet 1994; 27: 19-31.
91. Marcos A, Varela P, Santacruz I, Munoz-Velez A, Morande G. Nutritional status and immunocompetence in eating disorders. A comparative study. Eur J Clin Nutr 1993; 47: 787-793.
92. Lapchak P A, Araujo D M. Interleukin-2 regulates monoamine and opioid peptide release from the hypothalamus. Neuroreport 1993; 4: 303-306.
93. Maimone D, Cioni C, Rosa S, Macchia G, Aloisi F, Annunziata P. Norepinephrine and vasoactive intestinal peptide induce IL-6 secretion by astrocytes: synergism with IL-1 beta and TNF alpha. J Neuroimmunol 1993; 47: 73-81.
94. Eskay R L, Eiden L E. Interleukin-1 alpha and tumor necrosis factor-alpha differentially regulate enkephalin, vasoactive intestinal polypeptide, neurotensin, and substance P biosynthesis in chromaffin cells. Endocrinology 1992; 130: 2252-2258.
95. Sun L, Ganea D. Vasoactive intestinal peptide inhibits interleukin (IL)-2 and IL-4 production through different molecular mechanisms in T cells activated via the T cell receptor/CD3 complex. J Neuroimmunol 1993; 48: 59-69.
96. Ganea D, Sun L. Vasoactive intestinal peptide downregulates the expression of IL-2 but not of IFN gamma from stimulated murine T lymphocytes. J Neuroimmunol 1993; 47: 147-158.
97. Xin Z, Tang H, Ganea D. Vasoactive intestinal peptide inhibits interleukin (IL)-2 and EL-4 production in murine thymocytes activated via the TCR/CD3 complex. J Neuroimmunol 1994; 54: 59-68.
98. Mathew R C, Cook G A, Blum A M, Metwali A, Felman R, Weinstock J V. Vasoactive intestinal peptide stimulates T lymphocytes to release EL-5 in murine Schistosoma mansoni infection. J Immunol 1992; 148: 3572-3577.
99. Alam R, Pazdrak K, Stafford S, Forsythe P. The interleukin-5/receptor interaction activates Lyn and Jak2 tyrosine kinases and propagates signals via the Ras-Raf-1-MAP kinase and the Jak-STAT pathways in eosinophils. Int Arch Allergy Immunol 1995; 107: 226-227.
100. Holden R J, Mooney P A. Schizophrenia is a diabetic brain state: an elucidation of impaired neuronietabolism. Med Hypotheses 1994; 43: 420-435.
101. Xu C T, Pan B R, Wang Y M. [Study on the peptides of serum and gastric juice in patients with gastric cancer.] Chung Hua I Hsueh Tsa Chih 1993; 52: 32-35.
102. Taylor J E. Human small cell lung cancer cells express high affinity naloxone-insensitive [125I]-endorphin binding sites. Life Sci 1994; 56: PL97-PL102.
103. Povoski S P, Zhou W, Longnecker D S, Bell R H Jr. Cholecystokinin receptor chacterization and cholecystokinin-A receptor messenger RNA expression in transgenic mouse pancreatic carcinomas and dysplastic pancreas. Oncol Res 1994; 6: 411-417.
104. Liu C D, Balasubramaniam A, Saxton R E, Paiva M, McFadden D W. Human pancreatic cancer growth is inhibited by peptide YY and BIM-43004-1. J Surg Res 1995; 58: 707-712.
105. Motoyama T, Katayama Y, Watanabe H, Okazaki E, Shibuya H. Functioning ovarian carcinoids induce severe constipation. Cancer 1992; 70: 513-518.
106. Kuvshinoff B W, Nussbaum M S, Richards A I, Bloustein P, McFadden D W. Neuropeptide Y secretion from a malignant extraadrenal retroperitoneal paraganglioma. Cancer 1992; 70: 2350-2353.
107. Lertprasertsuke N, Tsutsumi Y. Neuroendocrine carcinoma of the urinary bladder: case report and review of the literature. Jpn J Clin Oncol 1991; 21: 203-210.
108. Funakoshi A, Yasunami Y, Ryu S, Shinozaki H, Jimi A, Ikeda S. Acetylcholine regulates glucagon secretion from human glucagonoma cells. J Gastroenterol 1994; 29: 797-799.
109. Terzic M, Stimec B, Sulovic V, Plecas D, Vojdovic L J. Is there a link between beta-endorphin and diabetes in pregnancy? Clin Exp Obstet Gynecol 1994; 21: 91-93.
110. Evans A A, Hughes S, Smith M E. Delta-opioid peptide receptors in muscles from obese diabetic and normal mice. Peptides 1995; 16: 361-364.
111. Wallengren J, Badendick K, Sundler F, Hakanson R, Zander E. Innervation of the skin of the forearm in diabetic patients: relation to nerve function. Acta Dermatol Venereol 1995; 75: 37-42.
112. Properzi G, Francavilla S, Poccia G et al. Early increase precedes a depletion of VIP and PGP-9.5 in the skin of insulin-dependent diabetics - correlation between quantitative immunohistochemistry and clinical assessment of peripheral neuropathy. J Pathol 1993; 169: 269-277.
113. Nowak T V, Chey W W, Chang T M, Weisbruch J P, Fouquet G. Effect of streptozotocin-induced diabetes mellitus on release of vasoactive intestinal polypeptide from rodent small intestine. Dig Dis Sci 1995; 40: 828-836.
114. Sipols A J, Baskin D G, Schwartz M W. Effect of intracerebroventricular insulin infusion on diabetic hyperphagia and hypothalamic neuropeptide gene expression. Diabetes 1995; 44: 147-151.
115. Bottcher G, Ekman R, Lundqvist G, Ahren B, Sundler F. Pancreatic peptide YY in alloxan diabetic mice. Pancreas 1994; 9: 469-474.
116. Koiwa M, Shiga H, Nakamura H, Yoshino S. [Role of opioid peptide in rheumatoid arthritis - detection of beta-endorphin in synovial tissue.] Arerugi 1992; 41: 1423-1429.
117. Suzuki N, Yoshino S, Nakamura H. [A study of opioid peptides in synovial fluid and synovial tissue in patients with rheumatoid arthritis.] Arerugi 1992; 41: 615-620.
118. Appelgren A, Appelgren B, Eriksson S et al. Neuropeptides in temporomandibular joints with rheumatoid arthritis: a clinical study. Scand J Dent Res 1991; 99: 519-521.
119. Holmlund A, Ekblom A, Hansson P, Lind J, Lundeberg T, Theodorsson E. Concentrations of neuropeptides substance P, neurokinin A, calcitonin gene-related peptide, neuropeptide Y and vasoactive intestinal polypeptide in synovial fluid of the human temporomandibular joint. A correlation with symptoms, signs and arthroscopic findings. Int J Oral Maxillofac Surg 1991; 20: 228-231.
120. Arnalich F, de Miguel E, Ferez-Ayala C et al. Neuropeptides and interleukin-6 in human joint inflammation relationship between intraarticular substance P and interleukin-6 concentrations. Neurosci Lett 1994; 170: 251-254.
121. Hernanz A, De Miguel E, Romera N, Perez-Ayala C, Gijon J, Arnalich F. Calcitonin gene-related peptide II, substance P and vasoactive intestinal peptide in plasma and synovial fluid from patients with inflammatory joint disease. Br J Rheumatol 1993; 32: 31-35.
122. Jorgensen C, Sany J. Modulation of the immune response by the neuro-endocrine axis in rheumatoid arthritis. Clin Exp Rheumatol 1994; 12: 435-441.
123. Ekdahl C, Ekman R, Petersson I, Svensson B. Dynamic training and circulating neuropeptides in patients with rheumatoid arthritis: a comparative study with healthy subjects. Int J Clin Pharmacol Res 1994; 14: 65-74.
124. Raziuddin S, Abu-Eshy S, Sheikha A. Peripheral T-cell lymphomas. Immunoregulatory cytokine (interleukin-2, interleukin-4, and interferon-gamma) abnormalities and autologous mixed lymphocyte reaction. Cancer 1994; 74: 2843-2849.
125. Hsu S M, Hsu P L. Autocrine and paracrine functions of cytokines in malignant lymphomas. Biomed Pharmacother 1994; 48: 433-444.
126. Hsu S M, Hsu P L. The nature of Reed-Sternberg cells: phenotype, genotype, and other properties. Crit Rev Oncogenes 1994; 5: 213-245.
127. Huang M, Wang J, Lee P et al. Human non-small cell lung cancer cells express a type 2 cytokine pattern. Cancer Res 1995; 55: 3847-3853.
128. Warren H S, Kinnear B F, Phillips J H, Lander L L. Production of IL-5 by human NK cells and regulation of IL-5 secretion by IL-4, IL-10, and EL-12. J Immunol 1995; 154: 5144-5152.
129. Burlinson E L, Drakes M L, Wood P J. Differential patterns of production of granulocyte macrophage colony stimulating factor, IL-2, IL-3 and IL-4 by cultured islets of Langerhans from non-obese diabetic and non-diabetic strains of mice. Int Immunol 1995; 7: 79-87.
130. Wegmann D R, Gill R G, Norbury-Glaser M, Schloot N, Daniel D. Analysis of the spontaneous T cell response to insulin in NOD mice. J Autoimmun 1994; 7: 833-843.
131. Taylor D J. Interleukin-4 (IL-4) induces down-modulation and shedding of the p55 tumour necrosis factor receptor and inhibits TNF alpha's effect on rheumatoid synovial fibroblasts. Rheumatol Int 1994; 14: 21-25.
132. Bansal A S, Oilier W, Marsh M N, Pumphrey R S, Wilson PB. Variations in serum sCD23 in conditions with either enhanced humoral or cell-mediated immunity. Immmunology 1993; 79: 285-289.
133. Dezube B J, Sherman M L, Fridovich-Keil J L, Allen-Ryan J, Pardee AB. Down-regulation of tumor necrosis factor expression by pentoxifylline in cancer patients: a pilot study. Cancer Immunol Immunother 1993; 36: 57-60.
134. Breuillé D, Farge M C, Rosé F, Arnal M, Attaiz D, Obled C. Pentoxifylline decreases body weight loss and muscle protein wasting characteristics of sepsis. Am J Physiol 1993; 265: E660-E666.
135. Chen Y L, Le-Vraux V, Giroud J P, Chauvelot-Moachon L. Anti-tumor necrosis factor properties of non-peptide drugs in acute-phase responses. Eur J Pharmacol 1994; 27: 319-327.
136. Bertini R, Garattini S, Delgado R, Ghezzi P. Pharmacological activities of chlorpromazine involved in the inhibition of tumor necrosis factor production in vivo in mice. Immunology 1993; 79: 217-219.
137. Weglicki W B, Phillips T M. Pathobiology of magnesium deficiency: a cytokine/neurogenic inflammation hypothesis. Am J Physiol 1992; 263: R734-737.
138. 2+ deficiency by substance P receptor inhibition. Circ Res 1994; 74: 1009-1013.
139. Purasiri P, Murray A, Richardson S, Heys S D, Horrobin D, Eremin O. Modulation of cytokine production in vivo by dietary essential fatty acids in patients with colorectal cancer. Clin Sci Colch 1994; 87: 711-717.
140. Ansel J C, Brown J R, Payan D G, Brown M A. Substance P selectively activates TNF-alpha gene expression in murine mast cells. J Immunol 1993; 150: 4478-4485.
141. Luber-Narod J, Kage R, Leeman S E. Substance P enhances the secretion of tumor necrosis factor-alpha from neuroglial cells stimulated with lipopolysaccharide. J Immunol 1994; 152: 819-824.
142. Holden R J, Mooney P A. Interleukin-1β: a common cause of Alzheimer's disease and diabetes mellitus. Med Hypotheses 1994; 45: 559-571.
143. Holden R J, Pakula I S. Immunological influences in attention-deficit disorder and schizophrenia: is there a link between these two conditions? Med Hypotheses 1995; 45: 575-587.
144. Shintani F, Kanba S, Nakaki T et al. Interleukin-1 beta augments release of norepinephrine, dopamine, and serotonin in the rat anterior hypothalamus. J Neurosci 1993; 13:3574-3581.
145. Linthorst A C, Flachskamm C, Holsboer F, Reul J M. Local administration of recombinant human interleukin-1 beta in the rat hippocampus increases serotonergic neurotransmission, hypotnalamic-pituitary-adrenocortical axis activity, and body temperature. Endocrinology 1994; 135: 520-532.
146. Bhattacharya S K, Saraswati M. Effect of intracerebroventricularly administered insulin on brain monoamines and acetylcholine in euglycaemic and alloxan-induced hyperglycaemic rats. Ind J Exp Biol 1991; 29: 1095-1100.
147. Craft S, Dagogo-Jack D E, Wiethop B V et al. Effects of hyperglycemia on memory and hormone levels in dementia of the Alzheimer type: a longitudinal study. Behav Neurosci 1993; 107: 926-940.
148. Gemma C, De-Luigi A, De Simoni M G. Permissive role of glucocorticoids on interleukin-1 activation of the hypothalamic serotonergic system. Brain Res 1994; 651: 169-173.